BWL
AKBA icon

Bogart Wealth LLC’s Akebia Therapeutics AKBA Stock Holding History

Bogart Wealth LLC’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29 Hold
25
– – ﹤0.01% 1976
2026
Q1 		$35 Buy
+25
New +$34 ﹤0.01% 1783

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Bogart Wealth LLC's AKBA Position: Q2 2026 in Review

Bogart Wealth LLC held its Akebia Therapeutics (AKBA) position steady in Q2 2026 at 25 shares worth $29. The position accounts for ﹤0.01% of the portfolio, ranked #1976.

Bogart Wealth LLC first reported a position in AKBA in Q1 2026 and has held it in 2 quarters since. The position peaked at $35 in Q1 2026. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Bogart Wealth LLC held 25 shares of Akebia Therapeutics worth $29 as of Q2 2026.
  • Bogart Wealth LLC left its Akebia Therapeutics share count unchanged in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of Bogart Wealth LLC's portfolio in Q2 2026, its #1976 holding.
  • Bogart Wealth LLC first reported a position in Akebia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Bogart Wealth LLC's Akebia Therapeutics position peaked at $35 in Q1 2026.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Bogart Wealth LLC's 13F filing for Q2 2026, filed 24 Jul 2026.